Novartis is presenting clinical findings from more than 20 abstracts at the American Academy of Dermatology Annual Meeting, highlighting advances across its immunology portfolio in complex skin diseases. Key presentations include new Rhapsido (remibrutinib) data demonstrating changes in daily itch and hives severity scores at week one in patients with chronic spontaneous urticaria.
The company is also presenting Cosentyx (secukinumab) data comparing safety and flare prevention versus bimekizumab in hidradenitis suppurativa, along with four- and five-year efficacy data from pivotal trials. Angelika Jahreis, Global Head of Immunology Development, said the presentations “demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases.”
Presentations span multiple indications including remibrutinib in chronic spontaneous urticaria and secukinumab in hidradenitis suppurativa and psoriatic arthritis, with sessions scheduled for March 27-28, 2026.